Business Description
Crism Therapeutics Corp
ISIN : VGG042401007
Total Employee Number:
1Description
Crism Therapeutics Corp has developed a drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs. Its product ChemoSeed which is in its clinical trial phase, can be implanted directly into the tumour or the resection margin following the removal of a tumour. The company also provides consultancy and formulation services to its clients assisting them with pharmaceutical formulation and development.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.79 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 9.01 | |||||
Beneish M-Score | 5.24 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 37.7 | |||||
3-Year EPS without NRI Growth Rate | 38.1 | |||||
3-Year FCF Growth Rate | 46.8 | |||||
3-Year Book Growth Rate | -78.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.35 | |||||
Quick Ratio | 4.35 | |||||
Cash Ratio | 2.96 | |||||
Days Sales Outstanding | 835.87 | |||||
Days Payable | 406.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -81.1 | |||||
Shareholder Yield % | -21.24 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 56.71 | |||||
Operating Margin % | -812.99 | |||||
Net Margin % | -823.81 | |||||
EBITDA Margin % | -806.06 | |||||
FCF Margin % | -876.89 | |||||
OCF Margin % | -862.5 | |||||
ROE % | -135.9 | |||||
ROA % | -106.75 | |||||
ROIC % | -307.7 | |||||
3-Year ROIIC % | 0.18 | |||||
ROC (Joel Greenblatt) % | -780.33 | |||||
ROCE % | -134.11 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shiller PE Ratio | 0.14 | |||||
PS Ratio | 19.17 | |||||
PB Ratio | 4.26 | |||||
Price-to-Tangible-Book | 3.86 | |||||
EV-to-EBIT | -4.06 | |||||
EV-to-EBITDA | -4.09 | |||||
EV-to-Revenue | 32.92 | |||||
EV-to-FCF | -3.92 | |||||
| Price-to-Net-Current-Asset-Value | 5.74 | |||||
| Price-to-Net-Cash | 11.79 | |||||
Earnings Yield (Greenblatt) % | -24.67 | |||||
FCF Yield % | -22.49 |
GF Valueâ„¢
Crism Therapeutics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Crism Therapeutics Corp Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-16 11:00 | In 13 days | ||
| Second quarter earnings results for 2026 | 2026-09-15 | In 11 days | ||
| General meeting for 2025 | 2026-08-26 | 2.24 (+0.00%) | ||
| Annual report for 2025 | 2026-06-26 | 2.24 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-06-26 | 2.24 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-16 11:00 | 2.24 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-15 | 2.24 (+0.00%) | ||
| General meeting for 2024 | 2025-08-26 10:00 | 2.24 (+0.00%) | ||
| Annual report for 2024 | 2025-06-13 | 2.24 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-06-13 | 2.24 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Crism Therapeutics Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers